ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Univ. Of Pennsylvania Ordered to Review all NIH Research

October 11, 1985

$2.5 Million NCI Grant To Fund Brachytherapy Improvement

February 27, 2004

In Brief: Fidler Wins BMS Cancer Research Award; Thomas Cech To Head Howard Hughs Inst.

April 2, 1999

House Panel Recommends $642 Million Increase For NIH; $31 Million Increase For NCI

July 21, 1995

In Brief: Balch, Morton Head SSO; Schantz, Rosen Move To MSK; Old Directs US Branch Of Ludwig Inst.

May 10, 1991

Strategic Plan Identifies Goal; To Be The Authoritative Source For Cancer Information

May 21, 1999